Mantle cell lymphoma (MCL) is a distinct subtype of B-cell lymphoma; the complete response rate for standard therapies in use today is 85 - 90%. NVP-BEZ235 inhibits the PI3K/Akt/mTOR signaling axis at the level of both PI3K and mTOR. In this study, we analyzed the inhibitory effects of NVP-BEZ235 on mantle cell lines and its effects in combination with enzastaurin, everolimus and perifosine.
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy / Civallero, Monica; Cosenza, Maria; Marcheselli, Luigi; Pozzi, Samantha; Sacchi, Stefano. - In: EXPERT OPINION ON INVESTIGATIONAL DRUGS. - ISSN 1354-3784. - STAMPA. - 21:(2012), pp. 1597-1606. [10.1517/13543784.2012.719871]
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy
CIVALLERO, Monica;COSENZA, Maria;MARCHESELLI, Luigi;POZZI, Samantha;SACCHI, Stefano
2012
Abstract
Mantle cell lymphoma (MCL) is a distinct subtype of B-cell lymphoma; the complete response rate for standard therapies in use today is 85 - 90%. NVP-BEZ235 inhibits the PI3K/Akt/mTOR signaling axis at the level of both PI3K and mTOR. In this study, we analyzed the inhibitory effects of NVP-BEZ235 on mantle cell lines and its effects in combination with enzastaurin, everolimus and perifosine.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
